National trends in neoadjuvant chemotherapy utilization in patients with early-stage node-negative triple-negative breast cancer: the impact of the CREATE-X trial.
Christine RogersAdrienne N CobbJan I C LlorenLubna N ChaudharyMorgan K JohnsonChiang-Ching HuangMediget TeshomeAmanda L KongPuneet SinghChandler S CortinaPublished in: Breast cancer research and treatment (2023)
From 2014 to 2019, NAC utilization increased for patients with cT1-2N0M0 TNBC. Racial, socioeconomic, and access disparities were observed in who received NAC vs AC and warrants interventions to ensure equitable care.
Keyphrases
- neoadjuvant chemotherapy
- early stage
- lymph node
- sentinel lymph node
- transcription factor
- quality improvement
- locally advanced
- healthcare
- affordable care act
- palliative care
- clinical trial
- physical activity
- computed tomography
- study protocol
- phase iii
- image quality
- contrast enhanced
- phase ii
- rectal cancer
- radiation therapy
- dual energy
- magnetic resonance imaging
- positron emission tomography
- pain management
- double blind